TESARO (NASDAQ:TSRO) : The highest short term price target forecast on TESARO (NASDAQ:TSRO) is $93 and the lowest target price is $53. A total of 7 equity analysts are currently covering the company. The average price of all the analysts is $68.57 with a standard deviation of $16.43.
Shares of Tesaro, Inc. rose by 86.07% in the last five trading days and 77.81% for the last 4 weeks. Tesaro, Inc. is up 87.95% in the last 3-month period. Year-to-Date the stock performance stands at 60.65%. Also, Credit Suisse initiates coverage on TESARO (NASDAQ:TSRO). The rating major has initiated the coverage with outperform rating on the shares. The Analysts at Credit Suisse announces a current price target of $56 per share. The rating by the firm was issued on May 13, 2016.
TESARO (NASDAQ:TSRO) : Zacks Investment Research ranks TESARO (NASDAQ:TSRO) as 4, which is a Sell recommendation. 8 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. The average broker rating of 8 research analysts is 1, which indicates as a Strong Buy.
TESARO (NASDAQ:TSRO): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $74.00 and $72.89 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $84.91. The buying momentum continued till the end and the stock did not give up its gains. It closed at $84.05, notching a gain of 8.59% for the day. The total traded volume was 6,262,510 . The stock had closed at $77.40 on the previous day.
In an insider trading activity, The officer (VP of Finance & Administration), of Tesaro, Inc., English Edward C had unloaded 7,000 shares at $41.21 per share in a transaction on June 10, 2016. The total value of transaction was $288,470. The Insider information was revealed by the Securities and Exchange Commission in a Form 4 filing.
TESARO, Inc. (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK). The Company is also developing immuno-oncology programs by entering into a collaboration and exclusive license agreement with AnaptysBio, Inc., for the discovery and development of antibodies for several specified immuno-oncology targets.